Ticker: NTLA

Intellia Therapeutics (NTLA) shares fell 19% following a safety disclosure from its Phase 3 MAGNITUDE trial. While a liver issue in one patient raised concerns, analysts maintain varied outlooks. Investors should monitor the situation closely for potential recovery.

Cathie Wood's ARK Innovation ETF is eyeing biotech stocks CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA). CRISPR's stock is down 13% this year, with a promising gene-therapy product yet to deliver revenue. Intellia, down 27%, targets rare diseases but faces financial ...

Cathie Wood of ARK Invest is doubling down on stocks like Shopify (NYSE: SHOP), Intellia Therapeutics (NASDAQ: NTLA), and Adaptive Biotechnologies (NASDAQ: ADPT) amid recent downturns. Discover why these investments hold high-risk, high-reward potential in your portfolio.